VKTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

VK

Mkt Cap

$3.20B

Volume

7.15M

Next Earnings

October 28th

Loading chart

VK

VKTXViking Therapeutics, Inc

VKTX

Pay with—

Available Balance0.00

VK

Mkt Cap

$3.48B

Volume

7.15M

Next Earnings

October 28th

Chart Financials Earnings News About Insider Filings

Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to KnowViking Therapeutics (VKTX) declined 8.26% on October 16, 2026, significantly underperforming the S&P 500's 1.09% loss. The stock has fallen 6.78% over the past month, lagging the Medical sector's 2.68% gain. The company faces negative earnings forecasts with an expected EPS of -$1 for the upcoming quarter and -$4.46 for the full year, though it maintains a Zacks Rank #2 (Buy) rating.Zacks Investment Research · Oct 16, 2026

Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsightOver 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.GlobeNewswire Inc. · Oct 15, 2026

Viking Therapeutics Starts Phase III Development of Obesity PillViking Therapeutics announced the initiation of the SUNRISE phase III program to evaluate its oral VK2735 formulation for obesity treatment. The program consists of two studies targeting 560 adults each, with and without type 2 diabetes. Phase II results showed up to 12.2% mean weight loss at the highest dose versus 1.3% with placebo. Despite positive developments, VKTX stock declined 4.4% on the announcement day and is down 27.6% year-to-date.Zacks Investment Research · Oct 15, 2026

4 High-Risk Stocks Built for Big ReturnsThe article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize.The Motley Fool · Oct 14, 2026

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?Novo Nordisk shares fell 11.1% over the past month following disappointing Capital Markets Day guidance that lacked near-term clarity. The company faces headwinds from intensifying competition with Eli Lilly's obesity drugs, lower U.S. pricing pressure, and pipeline setbacks including the failed CagriSema trial. While long-term opportunities exist in rare diseases and next-generation GLP-1 candidates, short-term investors should wait for stabilization signs, though long-term holders may maintain positions given valuation discounts and market potential.Zacks Investment Research · Oct 12, 2026

Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.Oppenheimer analyst Jay Olson raised his price target on Viking Therapeutics to $120 from $100, implying a potential quadrupling from the current $28.50 price. The bullish call is based on positive maintenance trial data for VK2735, a GLP-1 and GIP agonist drug, which increased the probability of success from 80% to 90%. Wall Street consensus projects VK2735 could generate $1.5 billion in 2030 sales rising to $6.5 billion by 2035, potentially capturing market share from Eli Lilly's tirzepatide, which is expected to reach $80 billion in total sales by 2030.The Motley Fool · Oct 12, 2026

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?Viking Therapeutics is advancing its oral weight-loss drug VK2735 to Phase 3 trials, showing 12.2% weight loss in Phase 2 testing. However, the company faces significant competitive challenges from established players like Eli Lilly's Foundayo, which demonstrated better tolerability with lower discontinuation rates. While Viking's injectable formulation shows promise with potential monthly dosing differentiation, the biotech will struggle to gain market traction in an increasingly crowded obesity drug market dominated by incumbents.The Motley Fool · Oct 10, 2026

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to ConsiderViking Therapeutics (VKTX) closed at $28.53, up 2.88% and outperforming the S&P 500's 0.6% gain. However, the stock has declined 13.69% over the past month. The company is expected to report an EPS of -$1 (down 23.46% YoY) with annual earnings projected at -$4.46 per share and zero revenue. Despite negative earnings outlook, VKTX holds a Zacks Rank #2 (Buy) rating with a slight 0.16% upward revision in consensus EPS projections over the past 30 days.Zacks Investment Research · Oct 9, 2026

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should KnowViking Therapeutics (VKTX) declined 2.84% to $27.73, underperforming the S&P 500's 0.47% loss. The stock has fallen 12.72% over the past month, significantly trailing the Medical sector's 3.97% decline. The company is projected to report negative earnings of -$1 per share with a 23.46% year-over-year decline, and annual estimates show -$4.47 EPS with zero revenue. Despite these challenges, VKTX maintains a Zacks Rank #2 (Buy) rating with no recent changes to consensus estimates.Zacks Investment Research · Oct 8, 2026

LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?Eli Lilly's stock has declined 2.3% in three months despite strong business fundamentals, driven by valuation concerns and competition worries rather than operational deterioration. The company's GLP-1 drugs Mounjaro and Zepbound generated $27.7 billion in first-half 2026 sales, while newly launched oral pill Foundayo is gaining traction with coverage from all major PBMs. Lilly is successfully diversifying beyond GLP-1 with non-cardiometabolic revenues growing 121% in Q2, and the pipeline includes promising candidates like retatrutide. However, headwinds include pricing pressure, rising competition, and slower expected second-half growth.Zacks Investment Research · Oct 8, 2026

to start trading

VK

VKTXViking Therapeutics, Inc

VKTX

Pay with—

Available Balance0.00

Your PositionYou don't own any VKTX yet.

Related Tickers

Earnings